Artikel
COVID-19 research in Germany – a promising drug candidate from Tübingen
In Germany, as in the rest of the world, research into suitable drugs for the treatment of COVID-19 patients is in full swing. A drug that has been shown to be effective in preclinical studies and will soon be tested on patients is produced by a research company in Tübingen, Atriva Therapeutics GmbH . Founded in 2015, the company specialises in the development of antiviral therapies for severe respiratory diseases such as influenza or COVID-19. Chairman of the company's advisory board is the head of the office site of the German Research Platform for Zoonoses in Münster, Prof. Dr. Stephan